<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(5)</volume><submitter>Bolduc PN</submitter><pubmed_abstract>We herein report the discovery, synthesis, and evolution of a series of indazoles and azaindazoles as CNS-penetrant IRAK4 inhibitors. Described is the use of structure-based and property-based drug design strategically leveraged to guide the property profile of a key series into a favorable property space while maintaining potency and selectivity. Our rationale that led toward functionalities with potency improvements, CNS-penetration, solubility, and favorable drug-like properties is portrayed. In vivo evaluation of an advanced analogue showed significant, dose-dependent modulation of inflammatory cytokines in a mouse model. In pursuit of incorporating a highly engineered bridged ether that was crucial to metabolic stability in this series, significant synthetic challenges were overcome to enable the preparation of the analogues.</pubmed_abstract><journal>ACS medicinal chemistry letters</journal><pagination>714-721</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11089553</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A Tiny Pocket Packs a Punch: Leveraging Pyridones for the Discovery of CNS-Penetrant Aza-indazole IRAK4 Inhibitors.</pubmed_title><pmcid>PMC11089553</pmcid><pubmed_authors>Bolduc PN</pubmed_authors><pubmed_authors>Metrick C</pubmed_authors><pubmed_authors>Pfaffenbach M</pubmed_authors><pubmed_authors>Li P</pubmed_authors><pubmed_authors>Peterson EA</pubmed_authors><pubmed_authors>Chodaparambil JV</pubmed_authors><pubmed_authors>Gao F</pubmed_authors><pubmed_authors>Vera Rebollar J</pubmed_authors><pubmed_authors>Evans R</pubmed_authors><pubmed_authors>Henry KL</pubmed_authors><pubmed_authors>Fang T</pubmed_authors><pubmed_authors>Silbereis J</pubmed_authors><pubmed_authors>Xin Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Tiny Pocket Packs a Punch: Leveraging Pyridones for the Discovery of CNS-Penetrant Aza-indazole IRAK4 Inhibitors.</name><description>We herein report the discovery, synthesis, and evolution of a series of indazoles and azaindazoles as CNS-penetrant IRAK4 inhibitors. Described is the use of structure-based and property-based drug design strategically leveraged to guide the property profile of a key series into a favorable property space while maintaining potency and selectivity. Our rationale that led toward functionalities with potency improvements, CNS-penetration, solubility, and favorable drug-like properties is portrayed. In vivo evaluation of an advanced analogue showed significant, dose-dependent modulation of inflammatory cytokines in a mouse model. In pursuit of incorporating a highly engineered bridged ether that was crucial to metabolic stability in this series, significant synthetic challenges were overcome to enable the preparation of the analogues.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T17:59:56.478Z</modification><creation>2026-04-18T03:12:27.785Z</creation></dates><accession>S-EPMC11089553</accession><cross_references><pubmed>38746903</pubmed><doi>10.1021/acsmedchemlett.4c00102</doi></cross_references></HashMap>